Company news

ProMIS Neurosciences Inc. news in 2025

ProMIS Neurosciences Inc.'s news releases, calls and decks from 2025, newest first.

View company

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

December 18, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

December 10, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

December 1, 2025

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

December 1, 2025

ProMIS Neurosciences Announces Reverse Stock Split

November 24, 2025

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

November 12, 2025

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

November 3, 2025

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

October 22, 2025

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

September 3, 2025

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

August 13, 2025

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

July 29, 2025

ProMIS Neurosciences Announces Private Placement Financing

July 28, 2025

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

July 22, 2025

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

July 21, 2025

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 17, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

March 31, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference

March 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

March 13, 2025

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

March 11, 2025

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease

February 25, 2025

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

January 28, 2025

ProMIS Neurosciences Issues Letter to Shareholders

January 12, 2025

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease

January 9, 2025

Decks in 2025